Elevated Interleukin-18 Levels Are Associated With the Metabolic Syndrome Independent of Obesity and Insulin Resistance

Objective—Activated innate immunity is thought to be involved in the pathogenesis of metabolic syndrome and type 2 diabetes. Interleukin-18 (IL-18) is a pleiotropic proinflammatory cytokine with important regulatory functions in the innate immune response. We sought to determine whether an elevated IL-18 concentration was a risk predictor for metabolic syndrome in a community population independent of obesity and hyperinsulinemia. Methods and Results—A representative general population, aged 27 to 77 years, without clinical diabetes was studied for clinical and biochemical risk factors for metabolic syndrome. Serum IL-18 concentration measured in 955 subjects correlated with metabolic syndrome traits including body mass index (BMI), waist circumference, triglyceride, high-density lipoprotein (inversely), and fasting glucose and insulin levels (all P<0.001). Mean IL-18 levels rose progressively with the increasing number of metabolic risk factors (ANOVA P<0.001). After adjusting for age, gender, BMI, and insulin levels, increasing IL-18 tertiles were associated with an odds ratio for metabolic syndrome of 1.0, 1.42, and 2.28, respectively (P trend=0.007). The graded risk relation was even stronger in nonobese subjects and not attenuated when adjusted for C-reactive protein and IL-6 levels. Conclusion—Our findings support the hypothesis that activation of IL-18 is involved in the pathogenesis of the metabolic syndrome.

[1]  Neil R. Powe,et al.  The Atherosclerosis Risk in Communities Study , 2006 .

[2]  J. Beilby,et al.  Monocyte Count, But Not C-Reactive Protein or Interleukin-6, Is an Independent Risk Marker for Subclinical Carotid Atherosclerosis , 2004, Stroke.

[3]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[4]  J. Pickup.  Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. , 2004, Diabetes care.

[5]  J. L. San Millán,et al.  Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. , 2004, The Journal of clinical endocrinology and metabolism.

[6]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[7]  J. Ascaso.  Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women , 2004 .

[8]  S. Blankenberg,et al.  Interleukin-18 and the Risk of Coronary Heart Disease in European Men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) , 2003, Circulation.

[9]  S. Haffner,et al.  Epidemic obesity and the metabolic syndrome. , 2003, Circulation.

[10]  Y. Aso,et al.  Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. , 2003, Diabetes care.

[11]  P. Macfarlane,et al.  Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.

[12]  J. Pankow,et al.  Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. , 2003, Diabetes.

[13]  G. Villuendas,et al.  Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women , 2003, Diabetologia.

[14]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[15]  G. Paolisso,et al.  Cytokine milieu tends toward inflammation in type 2 diabetes. , 2003, Diabetes care.

[16]  Antonio Abbate,et al.  Atherothrombosis, inflammation, and diabetes. , 2003, Journal of the American College of Cardiology.

[17]  J. Manson,et al.  C-Reactive Protein Is Independently Associated With Fasting Insulin in Nondiabetic Women , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[18]  Joachim Spranger,et al.  Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.

[19]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[20]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[21]  P. Ridker.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.

[22]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[23]  C. Lamendola,et al.  Differentiation Between Obesity and Insulin Resistance in the Association With C-Reactive Protein , 2002, Circulation.

[24]  L. Niskanen,et al.  Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. , 2002, American journal of epidemiology.

[25]  R. Marfella,et al.  Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress , 2002, Circulation.

[26]  D. Giugliano,et al.  Weight loss reduces interleukin-18 levels in obese women. , 2002, The Journal of clinical endocrinology and metabolism.

[27]  F. Cambien,et al.  Interleukin-18 Is a Strong Predictor of Cardiovascular Death in Stable and Unstable Angina , 2002, Circulation.

[28]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[29]  P. Macfarlane,et al.  The prognostic value of the electrocardiogram in the west of Scotland coronary prevention study , 2002 .

[30]  A. Tedgui,et al.  Expression of Interleukin-18 in Human Atherosclerotic Plaques and Relation to Plaque Instability , 2001, Circulation.

[31]  A. Hofman,et al.  Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. , 2001, The Journal of clinical endocrinology and metabolism.

[32]  S. Swain,et al.  Interleukin 18 , 2001, The Journal of experimental medicine.

[33]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[34]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[35]  H. Brenner,et al.  Association between C-reactive protein and features of the metabolic syndrome: a population-based study. , 2000, Diabetes care.

[36]  P. Wahl,et al.  Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. , 2000, American journal of epidemiology.

[37]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[38]  M. Visser,et al.  Elevated C-reactive protein levels in overweight and obese adults. , 1999, JAMA.

[39]  J. Beilby,et al.  Angiotensin-converting enzyme gene polymorphism and carotid wall thickening in a community population. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[40]  J. Beilby,et al.  Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS) , 1999, Circulation.

[41]  E. Bruckert,et al.  Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. , 1999, Circulation.

[42]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[43]  R. Bergman,et al.  Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the "minimal model". Insulin Resistance Atherosclerosis Study (IRAS) Investigators. , 1998, Annals of epidemiology.

[44]  H. Okamura,et al.  Interleukin-18: a novel cytokine that augments both innate and acquired immunity. , 1998, Advances in immunology.

[45]  Mohamed-Ali,et al.  Subcutaneous adipose tissue releases IL-6 but not tumour necrosis factor alpha in vivo , 1997 .

[46]  M. Laakso,et al.  How good a marker is insulin level for insulin resistance? , 1993, American journal of epidemiology.

[47]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.